No accelerated rate of decline in FEV1 or increased incidence of COPD seen in symptomatic TEPS versus asymptomatic, but more respiratory exacerbations
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 3, 2023 (HealthDay News) — Persons with tobacco exposure and preserved spirometry (TEPS) with symptoms (symptomatic TEPS) do not have accelerated rates of decline in forced expiratory volume in one second (FEV1) or chronic obstructive pulmonary disease (COPD) versus those with asymptomatic TEPS, but they do have more respiratory exacerbations, according to a study published in the Aug. 1 issue of the Journal of the American Medical Association.
William McKleroy, M.D., from the University of California in San Francisco, and colleagues defined the natural history of symptomatic TEPS in an extension of the SPIROMICS I multicenter study of persons aged 40 to 80 years who smoked cigarettes, with or without COPD, and controls without tobacco exposure or airflow obstruction. Data were included for 1,397 study participants: 226 with symptomatic TEPs and 269 with asymptomatic TEPS.
The researchers found that at a median follow-up of 5.76 years, the decline in FEV1 was â31.3 and â38.8 mL/y for participants with symptomatic and asymptomatic TEPS, respectively. The cumulative incidence of COPD was 33.0 and 31.6 percent for those with symptomatic and asymptomatic TEPS, respectively. Significantly more respiratory exacerbations were seen for participants with symptomatic versus asymptomatic TEPS (0.23 versus 0.08 exacerbations per person-year; rate ratio, 2.38).
“We found that many people who have a lot of primary tobacco exposure have the same symptoms as people who have COPD, but can’t be diagnosed with COPD, because their FEV1/forced vital capacity ratio is considered normal on spirometry,” McKleroy said in a statement. “This demonstrates a major gap in effective and compassionate care for tobacco-exposed persons.”
Several authors disclosed ties to the biopharmaceutical industry; support for the study was provided by several biopharmaceutical companies.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2023 HealthDay. All rights reserved.
